CRDL logo

CARDIOL THERAPEUTICS INC-A

CRDLNASDAQ
Earnings Nov 12US Equity
$1.20▲ $0.01 (+1.27%)
Latest quote
🔔
Track CRDL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.3%
7d▲ 3.5%
14d▲ 3.9%
30d▼ 29.5%
ytd▲ 24.8%
1y▲ 5.3%
🏦Market Cap
$142M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.19 – $1.21
52-Week Range
—
Volume (shares)
5,953
Avg Volume (shares)
—
Shares Outstanding
118.9M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+43.5%
CRDL logo

CARDIOL THERAPEUTICS INC-A

CRDL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$34M▼ −14.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$24M▼ −4.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
100.3M▲ +43.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$21M▼ −$9M YoY
StockOtter · stockotter.space

About CARDIOL THERAPEUTICS INC-A

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.